Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
Kowa said on July 17 that it has signed an exclusive licensing agreement with France-based Nicox for the development, manufacturing, and marketing of NCX470, a glaucoma and ocular hypertension drug candidate, outside of Asia. The Japanese firm had already secured…
To read the full story
Related Article
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- Kowa to Launch Japan PIII for Nicox-Partnered Glaucoma Drug
May 29, 2025
- Kowa Snags Japan Rights to Nicox’s Eye Drop Asset for Glaucoma
February 8, 2024
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…